Kevin Christopher Smith
Research Subjects
Kevin Christopher Smith has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
G. Daniel Schachter
2 shared publicationsGregory S. Storwick
Private Practice, Calgary, Alberta, Canada
1 shared publicationStephen L. Comite
Department of Dermatology, Mount Sinai School of Medicine, New York, New York
1 shared publication
Latest Publications
- 1 May 2011
- Published by Elsevier in Facial Plastic Surgery Clinics of North America
- Vol. 19 (2) , 253-260
YSGG 2790-nm Superficial Ablative and Fractional Ablative Laser Treatment
- 1 May 2011
- Published by Elsevier in Facial Plastic Surgery Clinics of North America
- Vol. 19 (2) , 253-260
YSGG 2790-nm Superficial Ablative and Fractional Ablative Laser Treatment
- 1 May 2011
- Published by Elsevier in Facial Plastic Surgery Clinics of North America
- Vol. 19 (2) , 235-240
Technical Characteristics of Fractional Light Devices
- 1 May 2011
- Published by Elsevier in Facial Plastic Surgery Clinics of North America
- Vol. 19 (2) , 235-240
Technical Characteristics of Fractional Light Devices
- 1 May 2010
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 36 (1) , 812-814
Ice Anesthesia for Injection of Dermal Fillers
- 1 May 2010
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 36 (1) , 812-814
Ice Anesthesia for Injection of Dermal Fillers
- 1 May 2009
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
- Vol. 29 (3) , S16-S18
Repair of Acne Scars With Dermicol-P35
Acne vulgaris is a prevalent skin condition that can cause disfiguring residual scarring. While the complete removal of acne scars is unlikely, several treatments exist that can improve the appearance of acne scars. Dermal fillers offer a simple, nonsurgical corrective procedure that can provide improved skin texture. Dermicol-P35 (Evolence [Ortho Dermatologics, Skillman, NJ]) is a new, highly purified, ribose cross-linked, porcine collagen-based dermal filler that has demonstrated low immunogenicity and results that persist for at least 12 months. This article presents the aesthetic results of a male patient treated with Dermicol-P35 for severe facial acne scars.
- 1 May 2009
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
- Vol. 29 (3) , S16-S18
Repair of Acne Scars With Dermicol-P35
Acne vulgaris is a prevalent skin condition that can cause disfiguring residual scarring. While the complete removal of acne scars is unlikely, several treatments exist that can improve the appearance of acne scars. Dermal fillers offer a simple, nonsurgical corrective procedure that can provide improved skin texture. Dermicol-P35 (Evolence [Ortho Dermatologics, Skillman, NJ]) is a new, highly purified, ribose cross-linked, porcine collagen-based dermal filler that has demonstrated low immunogenicity and results that persist for at least 12 months. This article presents the aesthetic results of a male patient treated with Dermicol-P35 for severe facial acne scars.
- 1 August 2008
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 14 (8) , 3
Reversible vs. nonreversible fillers in facial aesthetics: Concerns and considerations
Author(s): Smith, Kevin Christopher
- 1 August 2008
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 14 (8) , 3
Reversible vs. nonreversible fillers in facial aesthetics: Concerns and considerations
Author(s): Smith, Kevin Christopher
- 13 December 2007
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 20 (6) , 388-393
New fillers for the new man
Two new collagen-based lidocaine-containing dermal fillers, ArteSense/ArteFill (Artes Medical, San Diego, CA) and Evolence (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill has been available in the United States since 2006, and it is expected that Evolence will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.
- 13 December 2007
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 20 (6) , 388-393
New fillers for the new man
Two new collagen-based lidocaine-containing dermal fillers, ArteSense/ArteFill (Artes Medical, San Diego, CA) and Evolence (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill has been available in the United States since 2006, and it is expected that Evolence will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.
- 1 November 2007
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 120 (Supplement) , 67S-73S
Practical Use of Juv??derm: Early Experience
This article is intended to provide practical information on the use of Juvéderm Ultra and Juvéderm Ultra Plus injectable gel fillers and to highlight differences between the injection techniques and uses of these fillers and those of gel-particle suspensions. The author's purpose was to provide early information to clinicians who perform aesthetic surgery. The author discusses the properties of the Juvéderm family of products, compares these with particulate gel fillers, and makes recommendations for achieving optimal outcomes with Juvéderm as well as dermal fillers in general. When correcting relatively fine and superficial lines, or for first-time treatment of the lips, Juvéderm Ultra is preferred. Juvéderm Ultra Plus is useful for correction of deeper wrinkles and folds. Cohesive, homogenous gel fillers such as Juvéderm require gentle, gradual injection, which facilitates very accurate delivery to the site while minimizing the risk of disengagement of the needle from the Luer lock hub of the syringe. These fillers appear to remain in the desired location and do not flow away from the injection point into unintended areas, so that a somewhat smaller amount of filler is required for a given degree of correction. Both the Juvéderm preparations tend to blend in with the treated area in a shorter period of time compared with gel-particle suspensions. Finally, cohesive gels appear to be associated with a lesser degree of swelling in the 24-hour period after the procedure, particularly in the lips. Juvéderm Ultra and Juvéderm Ultra Plus are new-generation hyaluronic acid fillers used to treat superficial lines and deeper folds, respectively. They require administration by gentle, gradual, and precise injection.
- 1 November 2007
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 120 (Supplement) , 67S-73S
Practical Use of Juv??derm: Early Experience
This article is intended to provide practical information on the use of Juvéderm Ultra and Juvéderm Ultra Plus injectable gel fillers and to highlight differences between the injection techniques and uses of these fillers and those of gel-particle suspensions. The author's purpose was to provide early information to clinicians who perform aesthetic surgery. The author discusses the properties of the Juvéderm family of products, compares these with particulate gel fillers, and makes recommendations for achieving optimal outcomes with Juvéderm as well as dermal fillers in general. When correcting relatively fine and superficial lines, or for first-time treatment of the lips, Juvéderm Ultra is preferred. Juvéderm Ultra Plus is useful for correction of deeper wrinkles and folds. Cohesive, homogenous gel fillers such as Juvéderm require gentle, gradual injection, which facilitates very accurate delivery to the site while minimizing the risk of disengagement of the needle from the Luer lock hub of the syringe. These fillers appear to remain in the desired location and do not flow away from the injection point into unintended areas, so that a somewhat smaller amount of filler is required for a given degree of correction. Both the Juvéderm preparations tend to blend in with the treated area in a shorter period of time compared with gel-particle suspensions. Finally, cohesive gels appear to be associated with a lesser degree of swelling in the 24-hour period after the procedure, particularly in the lips. Juvéderm Ultra and Juvéderm Ultra Plus are new-generation hyaluronic acid fillers used to treat superficial lines and deeper folds, respectively. They require administration by gentle, gradual, and precise injection.
- 1 January 2007
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 33 (s1) , S88-S91
Ice Minimizes Discomfort Associated with Injection of Botulinum Toxin Type A for the Treatment of Palmar and Plantar Hyperhidrosis
The value of botulinum toxin type A (BTX-A) for treatment of palmar and plantar hyperhidrosis (HH) has been limited by injection pain, which in the past has generally required administration of a nerve block. We describe the successful use of ice applied to the intended injection point followed immediately by application of either ice or vibration to skin adjacent to the injection point to reduce discomfort associated with injection of BTX-A for the treatment of palmar and plantar HH. During needle insertion and injection of BTX-A, both the application of ice to the intended injection point followed by application of ice adjacent to the injection point (ice+ice) and the application of ice to the intended injection point followed by application of vibration adjacent to the injection point have been preferred by our patients to nerve block. These two techniques allow efficient treatment of both hands and/or both feet in a single session. By eliminating the need for nerve blocks, the techniques described here will enlarge the pool of physicians who can administer BTX-A for palmar and plantar HH, and will enlarge the pool of patients who are willing to have this treatment.
- 1 January 2007
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 33 (s1) , S88-S91
Ice Minimizes Discomfort Associated with Injection of Botulinum Toxin Type A for the Treatment of Palmar and Plantar Hyperhidrosis
The value of botulinum toxin type A (BTX-A) for treatment of palmar and plantar hyperhidrosis (HH) has been limited by injection pain, which in the past has generally required administration of a nerve block. We describe the successful use of ice applied to the intended injection point followed immediately by application of either ice or vibration to skin adjacent to the injection point to reduce discomfort associated with injection of BTX-A for the treatment of palmar and plantar HH. During needle insertion and injection of BTX-A, both the application of ice to the intended injection point followed by application of ice adjacent to the injection point (ice+ice) and the application of ice to the intended injection point followed by application of vibration adjacent to the injection point have been preferred by our patients to nerve block. These two techniques allow efficient treatment of both hands and/or both feet in a single session. By eliminating the need for nerve blocks, the techniques described here will enlarge the pool of physicians who can administer BTX-A for palmar and plantar HH, and will enlarge the pool of patients who are willing to have this treatment.